Identifying Responders to Anti-TNF Therapy in Rheumatoid Arthritis
Author Information
Author(s): Dirk Koczan, Susanne Drynda, Michael Hecker, Andreas Drynda, Reinhard Guthke, Joern Kekow, Hans-Juergen Thiesen
Primary Institution: University of Rostock
Hypothesis
Can early gene expression profiling predict the response to anti-TNFα therapy in rheumatoid arthritis patients?
Conclusion
Early gene expression profiling can help identify biomarkers that predict the effectiveness of anti-TNFα treatment in rheumatoid arthritis patients.
Supporting Evidence
- 42 candidate genes were identified as differentially regulated in responders and nonresponders.
- Prediction accuracies of over 89% for seven gene pairs and 95% for ten gene triplets were achieved.
- The study highlights the importance of early gene expression changes in predicting treatment outcomes.
Takeaway
Doctors can look at certain genes in the blood to see if a medicine for arthritis will work for a patient, helping them choose the best treatment.
Methodology
RNA was extracted from blood cells of 19 rheumatoid arthritis patients before and after treatment, and gene expression was analyzed using microarray technology.
Potential Biases
Potential biases may arise from the small sample size and the lack of blinding in X-ray assessments.
Limitations
The study's findings may not apply to all rheumatoid arthritis patients due to genetic and clinical variability.
Participant Demographics
19 patients (15 females, 4 males; mean age 50.8 years; all Caucasian).
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website